We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Logos Biosystems

Logos Biosystems is the life science solutions of Aligned Genetics, Inc., dedicated to the development and commercial... read more Featured Products: More products

Download Mobile App




Automated Fluorescent Microbial Cell Counter Detects Urinary Tract Infection

By LabMedica International staff writers
Posted on 15 Jul 2020
Print article
Image: The QUANTOM Tx Microbial Cell Counter is an image-based, automated cell counter that can identify and count individual bacterial cells in minutes (Photo courtesy of Logos Biosystems).
Image: The QUANTOM Tx Microbial Cell Counter is an image-based, automated cell counter that can identify and count individual bacterial cells in minutes (Photo courtesy of Logos Biosystems).
Urinary tract infections (UTI) accounted for around 400,000 hospitalizations, resulting in an estimated cost burden of approximately USD 2.8 billion in the USA. Between 50% and 60% of adult women will have at least one UTI in their life, and close to 10% of postmenopausal women indicate that they had a UTI in the previous year.

A rapid urinalysis is usually conducted upon presentation with UTI‐related symptoms in patients. A rapid urinalysis screens the urine for ketones, proteins, reducing substances, red blood cells (RBC), white blood cells (WBC), nitrites, and pH levels outside the normal range (4.5 to 8.0). The most common pathogen associated with UTI globally is Escherichia coli.

Gastroenterologists and their associates at the Sinai Hospital (Baltimore, MD, USA) obtained clean‐catch urine samples from 10 healthy control subjects with a negative urinalysis result and 11 subjects with suspected UTI with a positive urinalysis and culture result for E. coli. Urine samples that received a positive result were plated onto blood agar and MacConkey medium for growth analysis. Urine samples were analyzed using the QUANTOM Tx Microbial Cell Counter (Logos Biosystems, Annandale, VA, USA) upon reception from the microbiology laboratory.

The scientists reported that the mean cellular concentration for the 11 E. coli‐positive samples was 1.01 × 108 cells/mL (range = 2.5 × 107–3.29 × 108 ± SD = 8.9 × 107). The average cellular concentration for the 10 control samples was 2.35 × 106 cells/mL (range = 9.42 × 105–5.93 × 106 ± SD = 1.56 × 106). The difference in cellular concentration between the E. coli‐positive and control groups was found to be statistically significant.

The authors concluded that the automated microbial cell counter represents a significant step toward high throughput, reproducible microbial cell observation, and quantification. A significant difference in cellular concentration was observed between E. coli‐positive UTI samples and controls measured with an automated microbial cell counter. Thus, automated microbial cell counters may serve important roles as preliminary screening tools in clinical diagnostic settings. The study was published on July 4, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Sinai Hospital
Logos Biosystems


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Chagas Disease Test
LIAISON Chagas

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.